MEI PHARMA, INC.

Analyst Reco. MEI Pharma, Inc. Börse Stuttgart

Equities

MMI0

US55279B3015

Market Closed - Börse Stuttgart Other stock markets 15:55:57 14/04/2023 BST			5-day change	1st Jan Change
4.272 ^EUR	+0.38%		+1,961.78%	+1,757.39%

05-09	MEI Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	CI
04-11	MEI Pharma, Inc. Announces Strategic Plan to Leverage Recent Positive Voruciclib and ME-344 Clinical Data	CI

Analyst Reco.

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Stifel Adjusts Price Target on MEI Pharma to $7 From $8, Keeps Hold Rating	02-14	MT
Stifel Adjusts Price Target on MEI Pharma to $9 From $10, Maintains Hold Rating	27/09/23	MT
Stifel Adjusts MEI Pharma's Price Target to $10 From $0.50, Keeps Hold Rating	12/05/23	MT
Stifel Nicolaus Adjusts MEI Pharma Price Target to $0.50 From $2, Maintains Hold Rating	13/02/23	MT
HC Wainwright Adjusts Price Target on MEI Pharma to $2 From $5, Maintains Buy Rating	13/02/23	MT
Jefferies Downgrades MEI Pharma to Underperform From Hold, Adjusts Price Target to $0.10 From $0.40	08/02/23	MT
BTIG Downgrades MEI Pharma to Neutral From Buy	06/12/22	MT
Truist Securities Downgrades MEI Pharma to Hold From Buy	06/12/22	MT
Brookline Capital Markets Adjusts MEI Pharma Price Target to $15 From $20, Maintains Buy Rating	25/03/22	MT
BTIG Adjusts MEI Pharma's Price Target to $4 From $11, Reiterates Buy Rating	25/03/22	MT
Truist Securities Adjusts MEI Pharma's Price Target to $3 From $8, Reiterates Buy Rating	25/03/22	MT
Wells Fargo Downgrades MEI Pharma to Equalweight From Overweight, Adjusts Price Target to $2 From $13	25/03/22	MT
HC Wainwright Adjusts MEI Pharma's Price Target to $5 From $10, Reiterates Buy Rating	25/03/22	MT
Stifel Lowers MEI Pharma to Hold From Buy, Price Target to $2 From $6	25/03/22	MT
Jefferies Cuts MEI Pharma to Hold From Buy, Price Target to $1 From $4	25/03/22	MT
Jefferies Starts MEI Pharma at Buy With $4 Price Target	03/02/22	MT
MEI Pharma Says Treatment With Follicular Lymphoma Drug Candidate Shows Complete Response Rate of Over 35% in Mid-Stage Trial	30/11/21	MT
MEI Pharma Announces Pre-Specified Response Rate Exceeded in Dose-Escalation Study of Me-401 in Chronic Lymphocytic Leukemia and Follicular Lymphoma	31/05/17	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

BENEFIT NOW